Form 4: Cytokinetics Director John T. Henderson Executes Stock Option and Sells Shares
SEC Form 4 Filing
Director John T. Henderson exercised stock options and sold a portion of the acquired shares of Cytokinetics Inc. on April 15, 2025.
Summary
- On April 15, 2025, John T. Henderson, a director of Cytokinetics Inc., exercised stock options to acquire 20,000 shares of common stock at a price of $6.21 per share.
- Simultaneously, Henderson sold 3,190 shares of common stock at a price of $38.66 per share.
- Following these transactions, Henderson directly owns 66,348 shares and indirectly owns 83 shares through his spouse.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating neutral sentiment as it simply reports transactions.
Industry Context
This filing reflects routine transactions by a company insider and provides transparency into their holdings and trading activity. It's typical for directors to exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a director.
Key Dates
| Date | Description |
|---|---|
| 06/22/2015 | Date stock option became exercisable |
| 05/20/2025 | Expiration date of the stock option |
| 04/15/2025 | Date of stock option exercise and share sale |
| 04/16/2025 | Date of signature for the Form 4 filing |
Keywords
Cytokinetics, Director, Stock Option, Share Sale, Form 4, Henderson, CYTK
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.